Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 1/2015

01-01-2015 | Gastrointestinal Cancers (B Czito, Section Editor)

Update on Treatment of Liver Metastases: Focus on Ablation Therapies

Authors: Jeffrey Meyer, Seth Toomay

Published in: Current Oncology Reports | Issue 1/2015

Login to get access

Abstract

There is substantial and growing interest in the use of local therapies to treat patients with metastatic cancer, especially those deemed to have “oligometastatic” disease. Much of the literature to date consists of reports on metastasectomy for liver and lung metastases. Non-surgical minimally or non-invasive treatments including thermal ablation, irreversible electroporation, and high-dose radiation therapy (stereotactic ablative radiation therapy) can also be used in the treatment of primary and secondary tumors, including in the treatment of liver metastases. In this review, we discuss the rationale for using these ablative treatments in the treatment of liver metastases including similarities and differences between them.
Literature
1.
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.PubMedCrossRef
2.
Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–35.PubMedCrossRef
3.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.PubMed
4.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.PubMed
5.••
Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–57. A very important overview of controversies regarding the concept of oligometastatic disease. Discusses important issues inherent in clinical trials addressing treatment of oligometastatic disease.PubMedCrossRef
6.
Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol. 2014;31(2):180–6.PubMedCrossRef
7.
Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.PubMedCrossRef
8.
Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25 Suppl 1:S69–83.PubMedCrossRef
9.
Ng KK, Lam CM, Poon RT, Shek TW, Ho DW, Fan ST. Safety limit of large-volume hepatic radiofrequency ablation in a rat model. Arch Sug. 2006;141(3):252–8.CrossRef
10.
Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.PubMedCentralPubMedCrossRef
11.
Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14(1):1267–74.PubMedCrossRef
12.
Levit E, Bruners P, Gunther RW, Mahnken AH. Bile aspiration and hydrodissection to prevent complications in hepatic RFA close to the gallbladder. Acta Radiol. 2012;53(9):1045–8.PubMedCrossRef
13.
Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd 3rd GD, et al. American society of clinical oncology 2009 clinical evidence review of radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508.PubMedCrossRef
14.
Doyle MB, Chapman WC. Radiofrequency ablation for resectable colorectal hepatic metastases: is it time for a randomized controlled trial? Ann Surg. 2010;251(5):804–6.PubMedCrossRef
15.
Chen M-S, Li J-Q, Zheng Y, Guo R-P, Liang H-H, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.PubMedCentralPubMedCrossRef
16.
Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200.PubMedCrossRef
17.
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.PubMedCrossRef
18.
Lee EW, Wong D, Tafti BA, Prieto V, Totonchy M, Hilton J, et al. Irreversible electroporation in eradication of rabbit VX2 liver tumor. J Vasc Interv Radiol. 2012;23(6):833–40.PubMedCrossRef
19.
Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48.PubMedCrossRef
20.
21.
Lee EW, Chen C, Prieto EV, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010;255(2):426–33.PubMedCrossRef
22.
Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg. 2010;110(50):1305–9.PubMedCrossRef
23.
Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–21.PubMedCrossRef
24.
Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13(3):168–73.
25.••
Silk M, Wimmer T, Lee KS, Srimathveeravalli G, Brown KT, Kingham PT, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–8. Early clinical results of irreversible electroporation in the treatment of liver tumors located near critical structures.PubMedCrossRef
26.••
Cannon R, Ellis S, Hayes D, Narayanan G, Martin 2nd RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9. Early clinical results of irreversible electroporation for tumors near critical structures.PubMedCrossRef
27.
Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100.PubMedCrossRef
28.
Reed Jr GB. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol. 1966;48(4):597–611.PubMedCentralPubMed
29.
Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedCrossRef
30.
Radiobiology for the Radiologist. 7th ed. In: Hall EJ, Giaccia AJ, editors. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 41–42.
31.
Brown JM, Carlson DJ, Brenner DJ. Dose escalation, not “new biology”, can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1159–60.PubMedCentralPubMedCrossRef
32.
Song CW, Park I, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, et al. Is indirect cell death involved in response of tumors to stereotactic radiosurgery and stereotactic body radiation therapy? Int J Radiat Oncol Biol Phys. 2014;89(4):924–5.PubMedCrossRef
33.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9.PubMedCrossRef
34.
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.PubMedCentralPubMedCrossRef
35.
Lo SS, Teh BS, Wang JZ, Huang Z, Zook J, Price T, et al. Imaging changes after stereotactic body radiation therapy for lung and liver tumors. Expert Rev Anticancer Ther. 2011;11(4):613–20.PubMedCrossRef
36.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradely J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.PubMedCentralPubMedCrossRef
37.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.PubMedCrossRef
38.••
Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–42. Preliminary results from a trial of high-dose radiation for the treatment of liver metastases.PubMedCrossRef
39.
Yaes RJ, Kalend A. Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys. 1998;14(6):1247–59.CrossRef
40.
Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.PubMedCrossRef
41.
Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164–70.PubMed
42.
Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93.PubMedCrossRef
43.
44.
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.PubMedCrossRef
45.
Vokes EE, Weichselbaum RR. Concurrent chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8(5):911–34.PubMed
46.
Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947–52.PubMedCrossRef
47.
Yang W, Ahmed M, Elian M, el-SA H, Levchenko TS, Sawant RR, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257(3):685–96.PubMedCentralPubMedCrossRef
48.••
Formenti SC, Demaria S. Radiation therapy to convert the tumor to an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879–90. An important overview of word studying the interactions of radiation and the immune system.PubMedCrossRef
49.
den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumor immunity. Br J Cancer. 2006;95(7):896–905.CrossRef
50.
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.PubMedCentralPubMedCrossRef
Metadata
Title
Update on Treatment of Liver Metastases: Focus on Ablation Therapies
Authors
Jeffrey Meyer
Seth Toomay
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 1/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0420-2

Other articles of this Issue 1/2015

Current Oncology Reports 1/2015 Go to the issue

Head and Neck Cancers (E Hanna, Section Editor)

Prognosis and Biology in Esthesioneuroblastoma: the Emerging Role of Hyams Grading System

Gastrointestinal Cancers (B Czito, Section Editor)

Endoscopic Approaches for Early-Stage Esophageal Cancer: Current Options

Head and Neck Cancers (E Hanna, Section Editor)

Body Image: a Critical Psychosocial Issue for Patients With Head and Neck Cancer

Gastrointestinal Cancers (B Czito, Section Editor)

Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy

Head and Neck Cancers (E Hanna, Section Editor)

Defining Value-Driven Care in Head and Neck Oncology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits